JPRN-UMIN000026893已完成2 期
Randomized phase II study of clinical impact of ghrelin in elderly patients with gastric cancer in early postoperative period. - Clinical trial of ghrelin for elderly patients with gastric cancer in early postoperative period.
Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University0 个研究点目标入组 20 人开始时间: 2017年4月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ (2) Patients combined resection of other organs except for gallbradder and spleen. (3) Severe respiratory disease. (4)History of myocardial infarction or unstable angina pectoris within six months. (5) Liver cirrhosis or active hepatitis. (6) Chronic renal failure with hemodialysis. (7) Uncontrolled diabetes mellitus (HbA1c 9.0 or more). (8) Other unfeasible factors to perform study safely approved by attending surgeon.
研究者
相似试验
已完成
2 期
Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstructioJPRN-UMIN000003298Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University20
已完成
不适用
Randomized phase II study of clinical impact of ghrelin in esophageal cancer patients with cisplatin-based chemotherapy.JPRN-UMIN000004984Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University40
已完成
2 期
Randomized phase II study of clinical effects of ghrelin the perioperative period of esophagectomy with gastric tube reconstruction.Esophageal cancerJPRN-UMIN000007077Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University40
招募中
1 期
A phase 2 clinical trial of GH001 in patients with postpartum depressioEUCTR2021-006879-42-NLGH Research Ireland Limited15
尚未招募
2 期
A clinical study of a herbal formulation DRDC/2022/040 on symptoms of Gastroesophageal reflux disease (GERD)CTRI/2023/08/056221Dabur Research Development Centre Dabur India Limited